|
Sign In to gain access to subscriptions and/or personal tools.
|
Systemic lupus erythematosus and the risk of malignancy
J Cibere
Arthritis Research Centre of Canada, Vancouver, Canada
J Sibley
Department of Medicine, Division of Rheumatology, University of Saskatchewan, Saskatoon, Canada; Department of Medicine, Royal University Hospital, Saskatoon, SK, Canada S7N 0W8; sibleyj{at}duke.usask.ca
M Haga
Department of Medicine, Division of Rheumatology, University of Saskatchewan, Saskatoon, Canada
The objective of this study was to determine the relative risks of malignancy and of site-specific malignancies in patients with systemic lupus erythematosus (SLE).
A cohort of 297 patients (91% Caucasian) with SLE were seen between 1975 and 1994 and followed for a mean of 12 years at the University of Saskatchewan Rheumatic Disease Unit. Expected cancer incidence rates were determined based on Province of Saskatchewan population statistics matched to each study patient for age, sex and calendar year of follow-up. Standardized incidence ratios (SIRs) of observed to expected cancers and 95% confidence intervals (95% CI) were calculated.
A total of 27 cases of cancer were observed, whereas only 16.9 were expected (SIR 1.59 (95% CI 1.05–2.32)). For site-specific malignancies, an excess of cancer of the cervix (SIR 8.15 (95% CI 1.63–23.81)) as well as hemopoietic malignancy (SIR 4.9 (95% CI 1.57–11.43)) was found. The hemopoietic cancers were predominantly non-Hodgkin's lymphoma (SIR 7.01 (95% CI 1.88–17.96)). We did not find an association of malignancy with known risk factors, including use of cytotoxic agents.
Increased risk of malignancy, notably non-Hodgkin's lymphoma and perhaps cervical cancer, should be regarded as a complication of SLE.
Key Words: systemic lupus erythematosus • non-Hodgkin's lymphoma • malignancy • cervical cancer
Lupus, Vol. 10, No. 6,
394-400 (2001)
DOI: 10.1191/096120301678646128
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
L.-S. TAM, P. K.S. CHAN, S. C. HO, M. M.Y. YU, S.-F. YIM, T.-H. CHEUNG, M. C.S. WONG, and E. K. LI
Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus -- A Prospective Cohort Study
J Rheumatol,
February 1, 2010;
37(2):
330 - 340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Gayed, S Bernatsky, R Ramsey-Goldman, A. Clarke, and C Gordon
Lupus and cancer
Lupus,
May 1, 2009;
18(6):
479 - 485.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Bernatsky, M. Hudson, J. Pope, J. Markland, D. Robinson, N. Jones, P. Docherty, M. Abu-Hakima, S. LeClerc, J. Dunne, et al.
Reports of abnormal cervical cancer screening tests in systemic sclerosis
Rheumatology,
February 1, 2009;
48(2):
149 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Ruiz-Irastorza, A Ugarte, M V Egurbide, M Garmendia, J I Pijoan, A Martinez-Berriotxoa, and C Aguirre
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus
Ann Rheum Dis,
June 1, 2007;
66(6):
815 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Smedby, E. Baecklund, and J. Askling
Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2006;
15(11):
2069 - 2077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, E. A. Engels, R. M. Pfeiffer, G. Gridley, L. Mellemkjaer, J. H. Olsen, K. F. Kerstann, W. Wheeler, K. Hemminki, M. S. Linet, et al.
Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.
J Natl Cancer Inst,
September 20, 2006;
98(18):
1321 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Zintzaras, M. Voulgarelis, and H. M. Moutsopoulos
The Risk of Lymphoma Development in Autoimmune Diseases: A Meta-analysis
Arch Intern Med,
November 14, 2005;
165(20):
2337 - 2344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B-C Chun and S-C Bae
Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang Lupus Cohort in Seoul, Korea
Lupus,
August 1, 2005;
14(8):
635 - 638.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Bernatsky, A. Clarke, R. Ramsey-Goldman, L. Joseph, J.-F. Boivin, R. Rajan, A. D. Moore, M.-H. Leung, A. Allen, and C. Gordon
Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus
Rheumatology,
September 1, 2004;
43(9):
1178 - 1181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O Ragnarsson, G Grondal, and K Steinsson
Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus
Lupus,
September 1, 2003;
12(9):
687 - 691.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Hrycek, D Kokocinska, J Kosmider, and B Konieczny
Letter to the Editor
Lupus,
February 1, 2003;
12(2):
149 - 152.
[PDF]
|
|
|
|
|
|
|
M Abu-Shakra, M Ehrenfeld, and Y Shoenfeld
Systemic lupus erythematosus and cancer: associated or not?
Lupus,
March 1, 2002;
11(3):
137 - 144.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G R. Hughes
Lupus patients are protected from cancer
Lupus,
December 1, 2001;
10(12):
833 - 834.
[PDF]
|
|
|
|
|
|
|
Y Xu and P H Wiernik
Systemic lupus erythematosus and B-cell hematologic neoplasm
Lupus,
December 1, 2001;
10(12):
841 - 850.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R Ramsey-Goldman and A E Clarke
Double trouble: are lupus and malignancy associated?
Lupus,
June 1, 2001;
10(6):
388 - 391.
[PDF]
|
|
|
|
|
